1. Characterization of novel phage pK3–24 targeting multidrug-resistant Klebsiella pneumoniae and its therapeutic efficacy in Galleria mellonella larvae
- Author
-
Junxia Feng, Xiaohu Cui, Bing Du, Jinfeng Chen, Guanhua Xue, Lin Gan, Yanling Feng, Zheng Fan, Yuehua Ke, Jinghua Cui, Tongtong Fu, Hanqing Zhao, Chao Yan, Ziying Xu, Yang Yang, Zihui Yu, Lijuan Huang, Shuo Zhao, Ziyan Tian, Zanbo Ding, Yujie Chen, Zhoufei Li, and Jing Yuan
- Subjects
Klebsiella pneumoniae ,Phage ,Phage therapy ,Biofilm ,Genomic analysis ,Microbiology ,QR1-502 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Klebsiella pneumoniae is a common, conditionally pathogenic bacterium that often has a multidrug-resistant phenotype, leading to failure of antibiotic therapies. It can therefore induce serious diseases, including community-acquired pneumonia and bloodstream infections. As an emerging alternative to antibiotics, phages are considered key to solving the problem of drug-resistant bacterial infections. Here, we report a novel phage, pK3–24, that mainly targets ST447 K. pneumoniae. Phage pK3–24 is a T7-like short-tailed phage with a fast adsorption capacity that forms translucent plaques with halos on bacterial lawns. The optimal multiplicity of infection (MOI) is 0.01, and the average burst size is 50 PFU/mL. Phage pK3–24 shows environmental stability, surviving at below 50 °C and at pH values of 6–10. It has a double-stranded DNA genome of 40,327 bp and carries no antibiotic-resistance, virulence, or lysogeny genes. Phylogenetic analysis assigned phage pK3–24 to the genus Przondovirus as a new species. Phage pK3–24 inhibited the production of biofilm. Moreover, treatment with pK3–24 at doses with an MOI > 1 effectively reduced the mortality of Galleria mellonella larvae infected with ST447 K. pneumoniae.
- Published
- 2024
- Full Text
- View/download PDF